ALSO NOTED: Study questions "black box" on droperidol; Amilyn gets pen-injector OK;

> A new Mayo Clinic study seems to show that the FDA's "black box" warning of irregular heartbeat on the antinausea drug droperidol may be unnecessary. Report

> Amilyn Pharmaceuticals got the FDA nod for its pen-injector form of the diabetes drug Symlin. Release

> Lupin of India bought Rubamin Lab, a contract manufacturer, for an undisclosed amount. Report

And Finally... Do TV characters typically name-drop prescription drugs? Apparently so: Brand-name drugs were part of the TV-series plots some 705 times so far this year--and though only one drug maker admits to product placement marketing, the rest may not be far behind. Report

Suggested Articles

Pfizer isn't giving up in biosims. This week, it unveiled launches to three Roche blockbusters, with two already on the market.

Novo Nordisk is betting big on GLP-1 Saxenda in its global obesity push, but England's cost watchdog is unimpressed with the drug's long-term outlook.

Tecentriq didn’t show benefit against simple observation at delaying cancer recurrence or death in patients with muscle-invasive urothelial cancer.